

Marinomed at a glance

Marinomed Biotech AG is an Austrian biopharmaceutical company which was founded in 2006 and is listed on the prime market segment of the **Vienna Stock Exchange (VSE: MARI)**.

Marinomed has the vision to transform the lives of people suffering from diseases with limited or no treatment options in two key therapeutic areas: **virology** and **immunology**.

Marinomed's proprietary technology platforms **Marinosolv®** and **Carragelose®** provide the basis for treating diseases with unmet medical needs.



Business Areas

VIROLOGY



IMMUNOLOGY












SOLV4U



Platforms


Carragelose®

- Forms **non-specific layer** that protects mucosa from **viruses & pollen**
- Favorable safety profile
- Clinically validated & patent-protected
- **Marketed OTC product portfolio**

Product	Claims
 Nasal spray for adults and children 1y+	Prophylactic and supportive treatment of viral infections of the respiratory tract
 Nasal spray for children 1y+	
 Nasal spray for adults and children 1y+	Prophylactic and supportive treatment of viral infections of the respiratory tract & moistening of the mouth and throat
 Lozenges for adults and children 6y+	
 Throat spray for adults and children 1y+	Prophylactic and supportive treatment of viral infections of the respiratory tract; decongestant effect; anti-allergic
 Nasal spray for adults and children 1y+	
 Nasal and throat spray for adults and children 1y+	Prophylactic treatment of viral respiratory infections
 Nasal spray for adults and children 1y+*	Forms a protective layer on the nasal mucosa that acts as physical barrier against allergens
 Eye drops*	Lubricating and protective

*Launch anticipated for 2024

- **Solubilization technology** for poorly water-soluble compounds
- Significantly increases bioavailability
- Allows dose reduction & faster onset of action
- Clinically validated & patent protected
- Late-stage product developments **Budesolv** and **Tacrosolv**
- **Solv^{4U} Technology Partnerships** for external customers based on Marinosolv®



Development Pipeline

Pharmaceutical Products

Therapeutic area	Product Indication	Status	Pre-clinical	Phase I	Phase II	Phase III	Filing
IMMUNOLOGY	MAM-1004-1/Budesolv Treatment of severe allergic rhinitis	Filing in preparation	[Progress bar]				
	MAM-1003-1/Tacrosolv Severe inflammatory eye diseases	Phase II clinical study	[Progress bar]				
	MAM-1004-2 Autoimmune gastritis	Pre-clinical	[Progress bar]				
VIROLOGY	MAM-2001-1/Carravin Nasal congestion	Filing in progress	[Progress bar]				

OTC Medical Devices

Therapeutic area	Product Indication	Status	Pre-clinical	Clinical studies	Certification
IMMUNOLOGY	MAM-1001-4 nasal spray Prophylaxis of mild allergic rhinitis	Pre-launch	[Progress bar]		
	MAM-1001-3 eye drops Dry, irritated eyes	Pre-launch	[Progress bar]		
VIROLOGY	MAM-1001-1/Inhaleen Viral pneumonia	Clinical studies	[Progress bar]		

Follow us on @Marinomed Biotech AG



@Marinomed_AG

Please contact our Business development team at:
bd@marinomed.com | +43 2262 90300

